Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study

PURPOSE: Achondroplasia is caused by pathogenic variants in the fibroblast growth factor receptor 3 gene that lead to impaired endochondral ossification. Vosoritide, an analog of C-type natriuretic peptide, stimulates endochondral bone growth and is in development for the treatment of achondroplasia...

Descripción completa

Detalles Bibliográficos
Autores principales: Savarirayan, Ravi, Tofts, Louise, Irving, Melita, Wilcox, William R., Bacino, Carlos A., Hoover-Fong, Julie, Font, Rosendo Ullot, Harmatz, Paul, Rutsch, Frank, Bober, Michael B., Polgreen, Lynda E., Ginebreda, Ignacio, Mohnike, Klaus, Charrow, Joel, Hoernschemeyer, Daniel, Ozono, Keiichi, Alanay, Yasemin, Arundel, Paul, Kotani, Yumiko, Yasui, Natsuo, White, Klane K., Saal, Howard M., Leiva-Gea, Antonio, Luna-González, Felipe, Mochizuki, Hiroshi, Basel, Donald, Porco, Dania M., Jayaram, Kala, Fisheleva, Elena, Huntsman-Labed, Alice, Day, Jonathan R. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327889/
https://www.ncbi.nlm.nih.gov/pubmed/34341520
http://dx.doi.org/10.1038/s41436-021-01287-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327889/
https://www.ncbi.nlm.nih.gov/pubmed/34341520
http://dx.doi.org/10.1038/s41436-021-01287-7

Ejemplares similares